Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine 7/7 Schedule With Neratinib in Metastatic HER2-Positive Breast Cancer
NCT03377387Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2017
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2017; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03377387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377387.